Oral Presentation No. 10 Pharmacological therapy in patients with myocardial infarction with nonobstructive coronary arteries (MINOCA): long-term prognosis. (21st October 2022)

• Record Type: Journal Article
• Authors: Lopes, Vanessa; Moreira, Nádia; Fernandes, Rafaela; Cunha, Gil; Costa, Gonçalo; Monteiro, Eric; Fernandes, Diogo; Guimarães, Joana; Milner, James; Marinho, Vera; Monteiro, Sílvia; Monteiro, Pedro; Gonçalves, Francisco; Gonçalves, Lino
• Is Part Of: Cardiovascular research. Volume 118(2022)Supplement 2
• Publication Date: 2022-10-21
• Subjects: Cardiovascular system -- Diseases -- Periodicals; Cardiovascular system -- Periodicals; 616.1
• DOI: 10.1093/cvr/cvac157.002
• Languages: English
• ISSNs: 0008-6363

Abstract

Abstract: Background: The optimal management of myocardial infarction with nonobstructive coronary arteries (MINOCA) is still uncertain. This study sought to determine the association between pharmacological therapies after hospital discharge and the long-term prognosis of MINOCA patients. Material and methods: We analyzed patients consecutively admitted to the coronary care unit with myocardial infarction (MI). Multivariate analysis was performed to determine which drugs were implicated in the prognosis of MINOCA patients. The primary endpoint was all-cause mortality at 5 years. Results and conclusions: From a total of 3721 MI patients, MINOCA was identified in 11.6% ( n = 430), of whom 56 (13.0%) experienced the primary endpoint. Median age was 66 years (IQR 19), and 51.6% ( n = 222) of patients were male. At discharge, 81.2% of MINOCA patients were prescribed aspirin, 87.4% a statin, 78.6% beta-blockers, and 66.7% angiotensin-converting enzyme inhibitors (ACEI). MINOCA patients were less likely to be prescribed these medications compared to patients with obstructive coronary artery disease (all P < 0.001). 1.4% ( n = 6) of MINOCA patients died in the hospital, and the 5-year mortality rate was 13.0% ( n = 56). In multivariate Cox regression, treatment with ACEI at discharge was found to be independently associated with a 5-year mortality benefit (HR = 0.29, 95% CI 0.12–0.67, adjusted P = 0.004) in MINOCA patients. In conclusion, compared with patients with obstructive CAD, patients with MINOCA are less likely to be treated with secondary prevention drugs and are at lower risk of all-cause mortality during long-term follow-up. Treatment with ACEI seems to provide an additional mortality benefit in MINOCA patients.